3802 related articles for article (PubMed ID: 3259209)
1. In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2.
Gambacorti-Passerini C; Radrizzani M; Marolda R; Belli F; Sciorelli G; Galazka AR; Schindler JD; Cascinelli N; Parmiani G
Int J Cancer; 1988 May; 41(5):700-6. PubMed ID: 3259209
[TBL] [Abstract][Full Text] [Related]
2. Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Belli F; Sciorelli G; Ravagnani F; Galazka AR; Cascinelli N; Parmiani G
Cancer Res; 1989 Sep; 49(18):5230-4. PubMed ID: 2788498
[TBL] [Abstract][Full Text] [Related]
3. Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2.
Hersey P; Bindon C; Edwards A; Murray E; Phillips G; McCarthy WH
Int J Cancer; 1981 Dec; 28(6):695-703. PubMed ID: 6977498
[TBL] [Abstract][Full Text] [Related]
4. Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.
Ghosh AK; Dazzi H; Thatcher N; Moore M
Int J Cancer; 1989 Mar; 43(3):410-4. PubMed ID: 2784419
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects.
Marolda R; Belli F; Prada A; Villani F; Gambacorti-Passerini C; Galazka A; Parmiani G; Cascinelli N
Tumori; 1987 Dec; 73(6):575-84. PubMed ID: 3501624
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.
Kohler PC; Hank JA; Moore KH; Storer B; Bechhofer R; Hong R; Sondel PM
Cancer Invest; 1989; 7(3):213-23. PubMed ID: 2790538
[TBL] [Abstract][Full Text] [Related]
8. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
[TBL] [Abstract][Full Text] [Related]
9. Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1985 Jul; 45(7):3173-8. PubMed ID: 3924397
[TBL] [Abstract][Full Text] [Related]
10. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
Itoh K; Platsoucas CD; Balch CM
J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells.
Shimazaki C; Atzpodien J; Wisniewski D; Gulati SC; Kolitz JE; Fried J; Clarkson BD
Acta Haematol; 1988; 80(4):203-9. PubMed ID: 3146198
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells.
Taramelli D; Fossati G; Balsari A; Marolda R; Parmiani G
Int J Cancer; 1984 Dec; 34(6):797-806. PubMed ID: 6334655
[TBL] [Abstract][Full Text] [Related]
13. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes.
Sulé-Suso J; Arienti F; Melani C; Colombo MP; Parmiani G
Eur J Immunol; 1995 Oct; 25(10):2737-42. PubMed ID: 7589065
[TBL] [Abstract][Full Text] [Related]
14. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
Jpn J Cancer Res; 1988 Jan; 79(1):131-43. PubMed ID: 3128501
[TBL] [Abstract][Full Text] [Related]
15. Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy.
Slingluff CL; Darrow TL; Seigler HF
Ann Surg; 1989 Aug; 210(2):194-202. PubMed ID: 2787972
[TBL] [Abstract][Full Text] [Related]
16. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
de Vries JE; Spits H
J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.
Voss SD; Hank JA; Nobis CA; Fisch P; Sosman JA; Sondel PM
Cancer Immunol Immunother; 1989; 29(4):261-9. PubMed ID: 2787694
[TBL] [Abstract][Full Text] [Related]
20. Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer.
Paciucci PA; Holland JF; Glidewell O; Odchimar R
J Clin Oncol; 1989 Jul; 7(7):869-78. PubMed ID: 2661733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
